News


All News

Scottsdale, Ariz. - Medicis Pharmaceutical has received Food and Drug Administration clearance to market Perlane, a thicker formulation of the company's injectable dermal filler Restylane, for correction of moderate-to-severe facial folds and wrinkles.

Medicis' recent $9.8 million settlement of a whistleblower lawsuit stemming from alleged improper marketing of Loprox inspired the company to beef up its compliance program, a Medicis spokesman says.

There is more to treating skin of color than meets the eye. Cultural influences can be important factors in patients' maladies as well as issues of noncompliance and treatment choices. Learning about the culture is as important as learning about the physiology.

Dermatologist Robert S. Kirsner, M.D., Ph.D., has run five marathons - crossing the finish in one last year in an impressive 3:36.

Elk Grove Village, Ill. - Physicians who practice with compassion and know their limits are better able to treat their patients, according to Michael Greenberg, M.D., a dermatologist practicing in Elk Grove Village, Ill.

Virtually every modifier came about in response to some abuse by physicians that has been identified by the Centers for Medicare and Medicaid Services.

Professional financial planners have no incentive to get you to do a lot of buying and selling. They charge an annual fee based on the size of your investment portfolio.

You will need to refurbish everything from patient registration to back-end claims processing to make sure those high-deductible patients pay what they owe.

Recent regulations may bar, for the very first time, expert advisers to the FDA who receive money from either a pharmaceutical or device manufacturer from voting to approve that company's products.

Winston-Salem, N.C.-Two studies published in the April issue of the Archives of Dermatology suggest that oral lichen planus (OLP) responds well to methotrexate and oral erosive lichen planus (OELP) to pimecrolimus, news source Medscape reports.

Washington - Certain variants in the interleukin 10 (IL-10) promoter region can predict poor outcomes in patients with malignant melanoma, including tumor ulceration and recurrence, suggests research presented at the recent 60th annual meeting of the Society of Surgical Oncology, here.

South San Francisco, Calif. - Israel’s Ministry of Health has granted approval for biopharmaceutical firm Pain Therapeutics Inc., based here, to begin human testing of a new treatment for metastatic melanoma.

Washington - The child of a soldier just back from Iraq has been hospitalized after developing a reaction to his father’s smallpox vaccination, reports Reuters Health. At press time, the 2-year-old boy was in critical condition, but doctors expressed cautious optimism that he was improving.

Sheffield, England - British researchers report they have identified a means by which to quickly detect the presence of bacteria by using a light device activated by polymer molecules. According to a BBC news report, the technology could have significant application in wound healing.